Patent Cases

Shenzhen Tuozhu Technology Co., Ltd. et al. v.Stratasys, Inc. et al.

· IPR2025-00354

Shenzhen Tuozhu Technology seeks a Director Review after the PTAB denied institution of its IPR against Stratasys’s 8,747,097 patent. The petitioner argues the denial violates statutory requirements and recent guidance on Sotera stipulations. The request highlights examiner error and lack of settled expectations by the patent owner.

Shenzhen Tuozhu Technology Co., Ltd. et al. v.Stratasys, Inc. et al.

· IPR2025-00354

Stratasys, the owner of U.S. Pat. 8,747,097 covering 3‑D printing technology, has responded to a challenger’s request for Director Review, arguing the request is untimely and lacks a statutory basis. The patent owner urges the Director to deny the review.

Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.

· IPR2025-00351

Court decision.

iRhythm, Inc. v.Welch Allyn, Inc. et al.

· IPR2025-00376

An email from the PTAB Director informs Welch Allyn that iRhythm’s Director Review requests for multiple IPRs have been received, outlining a five‑business‑day deadline for a concise response and prohibiting new evidence.

Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.

· IPR2025-00351

The PTAB Director has received review requests for IPR2025-00349, -00350, and -00351. The petitioner must respond within five days, limited to five pages, with no new evidence.

POSCO Co., Ltd. et al. v.ArcelorMittal

· IPR2025-00371

POSCO has filed an IPR petition seeking cancellation of all 25 claims of ArcelorMittal’s hot‑stamped coated steel patent, alleging obviousness over a suite of prior‑art references. The petition argues that the references were not considered during prosecution and that a skilled artisan would have combined them to achieve the claimed inventions.

iRhythm, Inc. v.Welch Allyn, Inc. et al.

· IPR2025-00363

iRhythm has filed a petition for inter partes review of Welch Allyn’s U.S. Patent 10,159,422 covering a wearable ECG sensor. The challenger asserts that the claims are obvious over three prior‑art references—Matsumura, Jensen, and Ozguz—and asks the PTAB to cancel them.

Tesla, Inc. v.Intellectual Ventures II LLC

· IPR2025-00341

Tesla has filed an IPR petition seeking to invalidate five claims of Intellectual Ventures’ U.S. Pat. 7,181,743. The challenger argues the claims are obvious over the Welch whitepaper and related publications, and disputes any discretionary denial.

Therabody, Inc. v.Hyperice IP Subco, LLC et al.

· PGR2025-00013

Therabody successfully challenged Hyperice's patent claims in a PTAB proceeding focused on massaging devices. The Board found likelihood of unpatentability based on obviousness and statutory deficiencies, particularly regarding the combination of prior art references.

POSCO Co., Ltd. et al. v.ArcelorMittal

· IPR2025-00371

POSCO Co., Ltd. successfully petitioned the PTAB to institute an IPR against ArcelorMittal's patent, demonstrating a reasonable likelihood of prevailing on all 25 challenged claims. The Board found sufficient evidence across multiple grounds of obviousness (103) involving various prior art combinations.

patent denied · Dec 23, 2024

Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.

· IPR2025-00351

Stingray Group Inc. successfully secured institution of its IPR challenge against a patent covering multimedia content delivery systems. The Board found that Petitioner established a reasonable likelihood of prevailing across multiple grounds under 35 U.S.C. §§ 102 and 103, moving the case to the merits phase.

Tesla, Inc. v.Intellectual Ventures II LLC

· IPR2025-00341

The PTAB denied Tesla's IPR against Intellectual Ventures II over patent 7,181,743. The Board found that the prior art did not teach or suggest the specific 'event correlation capabilities' required by the challenged claims.

Twitch Interactive, Inc. et al. v.Razdog Holdings LLC

· IPR2025-00308

Twitch Interactive successfully challenged a patent claim in the PTAB, demonstrating a reasonable likelihood of prevailing on obviousness grounds. The Board adopted Petitioner's narrow construction of 'real time,' favoring transmission upon availability without significant delay over strict human-perception timing.

patent plaintiff favorable · Dec 23, 2024

Twitch Interactive, Inc. et al. v.Razdog Holdings LLC

· IPR2025-00307

Twitch Interactive successfully secured institution of its § 103 IPR challenge against Razdog Holdings LLC's patent. The Board adopted the Petitioner's interpretation of 'real time,' allowing the case to proceed to trial on all claims.

Evergreen Sweet House v.JV Evergreen Sweets And Treats & Ors.

Delhi High Court · 120343358

The Delhi High Court granted an interim injunction in favor of Evergreen Sweet House against JV Evergreen Sweets And Treats. The court found a prima facie case of passing off, noting that the plaintiff has been operating under the 'Evergreen' mark since 1963, establishing significant goodwill and prior use. Given the defendant's recent entry into the market and the likelihood of customer confusion on food delivery platforms, the court restrained the defendants from using the infringing mark until the final suit adjudication.

patent plaintiff favorable · Dec 21, 2024

Saint Gobain Construction Products UK Ltd. v.Mr.Tallam Uma Shankar Gupta

Madras High Court · 155598264

The Madras High Court allowed a petition seeking rectification of the Trade Marks Register, directing the removal of the mark 'GYPLOCK' (No. 3536418). The petitioner, Saint Gobain Construction Products UK Ltd., successfully argued that its established trademark 'GYPROC' was similar to the impugned mark and used on identical goods—building materials. Despite arguments regarding common trade terms ('GYP'), the court found the overall similarity between 'GYPROC' and 'GYPLOCK' likely to cause confusion, thereby protecting the purity of the register.

Mannheim (DE) Local Division · UPC-001091

pharma-aktiva GmbH, Hofer Kommanditgesellschaft, ALDI Nord Deutschland Stiftung & Co. KG, ALDI SE & Co. KG, ALDI SÜD Dienstleistungs-SE & Co. oHG v.G. Pohl-Boskamp GmbH & C. KG

G. Pohl-Boskamp GmbH & Co. KG, a pharmaceutical company marketing the head lice treatment NYDA®, filed an application for preliminary measures against pharma-aktiva GmbH and several ALDI group entities (ALDI SÜD, ALDI Nord, ALDI SE & Co. KG, and Hofer KG) for alleged infringement of European Patent EP 1 993 363 B1, which concerns a composition for combating ectoparasites and their eggs. The applicant challenged the sale of a competing lice spray marketed as 'Vitalis Läuse Spray' in Germany and 'ACTIV MED Läusespray' in Austria. The Local Chamber Mannheim issued an order on December 20, 2024, following an oral hearing on December 12, 2024, addressing the application for interim measures under Rule 206 RoP.

Luxembourg (LU) · UPC-001090

Alexion Pharmaceuticals, Inc. v.Samsung Bioepis NL B.V.

The Court of Appeal of the Unified Patent Court rejected Alexion Pharmaceuticals' appeal against the dismissal of its application for provisional measures against Samsung Bioepis concerning European Patent EP 3 167 888 B1 for a C5-binding antibody (eculizumab) used to treat paroxysmal nocturnal hemoglobinuria. The court held that the patent's claim 2 could not be corrected by interpretation to remove 22 extra amino acids at the N-terminus of SEQ ID NO:4, as the existence of the error and the precise correction were not sufficiently certain to the person skilled in the art. Consequently, the court found it more likely than not that claim 2 was insufficiently disclosed under Art. 83 EPC, and ordered Alexion to bear the costs of the appeal proceedings.

Munich (DE) Local Division · UPC-001089

HARTING Electric Stiftung & Co. KG v.Respondent

This procedural order concerns an application by HARTING Electric Stiftung & Co. KG for access to the case files of an ongoing patent infringement action between PHOENIX CONTACT GmbH & Co. KG (plaintiff) and Industria Lombarda Materiale Elettrico I.L.M.E. S.p.A. and ILME GmbH (defendants) concerning European Patent EP 3 602 692. HARTING, which had filed an opposition against the patent in suit before the European Patent Office (joined by defendant ILME GmbH), sought access to the briefs and evidence filed in the main infringement proceedings to properly defend its interests in both the opposition proceedings and related utility model infringement actions. The Local Chamber Munich held that an opponent in a pending opposition proceeding concerning the patent in suit has a legal interest in accessing the case files under Rule 262.1(b) RoP during the ongoing proceedings.

Munich (DE) Local Division · UPC-001088

Edwards Lifesciences Corporation v.Meril GmbH, Meril Life Sciences Pvt. Ltd., Meril Italy S.r.l.

Procedural order in a patent infringement action concerning European patent EP 3669828 before the Local Division Munich. The court granted both parties' Rule 263 requests to add Romania (which acceded to the Unitary Patent system on 1 September 2024) to the infringement action and counterclaim for revocation, and granted the claimant's request to amend its information request to require purchase documents. The court set the dispute value at €16 million, scheduled the oral hearing for 11 February 2025, and rejected requests for party and court experts.

Hamburg (DE) Local Division · UPC-001087

President and Fellows of Harvard College v.Respondent

This case concerns a patent infringement action (UPC_CFI_22/2023) involving European Patent EP4108782, owned by President and Fellows of Harvard College, against Vizgen, Inc. The dispute centers on Plaintiff Harvard's third request to amend the patent, filed on October 25, 2024, which was rejected by the Rapporteur's order of November 8, 2024. The Local Chamber Hamburg reviewed the order under Rule 333.1 RoP and confirmed the rejection, holding that approximately three months between the alleged reason for the amendment and the filing of the request was too long under Rule 30.2 RoP.

Luxembourg (LU) · UPC-001086

Alexion Pharmaceuticals, Inc. v.Amgen Technology (Ireland) Unlimited Company, Amgen N.V., Amgen GmbH, Amgen AB, Amgen S.A.S., Amgen s.r.l., Amgen Biofarmacêutica Lda., Amgen Zdravila D.O.O.

Alexion Pharmaceuticals, the proprietor of European Patent 3 167 888 B1 relating to the antibody eculizumab for treating paroxysmal nocturnal hemoglobinuria, sought provisional measures against Amgen, which markets BEKEMV®, a biosimilar of Soliris®. The Court of First Instance (Hamburg Local Division) dismissed Alexion's application, and Alexion appealed. The Court of Appeal rejected the appeal, holding that the patent's SEQ ID NO:4 sequence must be interpreted as including 22 extra amino acids at the N-terminus, and that Alexion had failed to demonstrate with sufficient certainty that the skilled person would correct this as an error, rendering the patent claim more likely than not insufficiently disclosed under Art. 83 EPC.

patent instituted · Dec 20, 2024

Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.

· IPR2025-00350

The PTAB notified parties that Director Review requests for three IPRs have been received. The petitioner has five business days to submit a concise response limited to the raised issues, with no new evidence allowed.

Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.

· IPR2025-00349

The PTAB issued an institution decision for IPR2025-00349 on June 13, 2025. A later director‑review request by the patent owner was filed after the 14‑day deadline and was deemed untimely, so the Board will not consider it.

patent denied · Dec 20, 2024

Webgroup Czech Republic, a.s. et al. v.DISH Technologies L.L.C. et al.

· IPR2025-00347

The USPTO denied Webgroup Czech Republic's request for Director Review of the Final Written Decisions in two IPRs challenging DISH Technologies patents.

patent instituted · Dec 20, 2024

Webgroup Czech Republic, a.s. et al. v.DISH Technologies L.L.C. et al.

· IPR2025-00347

The PTAB instituted inter partes review of DISH Technologies' adaptive‑bitrate streaming patent (claims 1‑16) and granted joinder to Webgroup Czech Republic and NKL Associates, aligning the case with the earlier fuboTV/MasterClass IPR.